Wimmer E, Ihrler S, Gires O, Streit S, Issing W, Bergmann C. Fibroblast growth factor receptor 4 single nucleotide polymorphism Gly388Arg in head and neck carcinomas. World J Clin Oncol 2019; 10(3): 136-148 [PMID: 30949443 DOI: 10.5306/wjco.v10.i3.136]
Corresponding Author of This Article
Christoph Bergmann, MD, PhD, Assistant Professor, Senior Lecturer, Surgeon, Department of Otorhinolaryngology, University of Duisburg-Essen, Hufelandstr. 55, Essen 45147, Germany. christoph.bergmann@uk-essen.de
Research Domain of This Article
Cell Biology
Article-Type of This Article
Basic Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Mar 24, 2019; 10(3): 136-148 Published online Mar 24, 2019. doi: 10.5306/wjco.v10.i3.136
Table 1 Table of chi-square test of association between fibroblast growth factor receptor 4 genotype (Gly/Gly, Gly/Arg or Arg/Arg) and other pathological variables
Table 2 Genotypes in patients and controls of fibroblast growth factor receptor 4 and calculated probability of gene distribution in second rows n (%)
Fibroblast growth factor receptor 4 genotypes
Cancer cases (n = 284)
Controls (n = 123)
Gly/Gly
188 (66.2)
55 (45)
0.65
0.47
Gly/Arg
84 (29.6)
60 (49)
0.3
0.42
Arg/Arg
12 (4.2)
8 (6)
0.03
0.09
Table 3 Table of chi-square test of association correlating fibroblast growth factor receptor 4 expression, lymph nodes and therapy
Fibroblast growth factor receptor 4 expression
low
high
n
P-value
Lymph nodes
N0, N1 and N2
479
459
938
0.0001
N3
117
58
175
Chemotherapy
No
403
269
672
0.0001
Yes
193
248
441
Table 4 Table of chi-square test of association between fibroblast growth factor receptor 4 genotypes (Gly/Gly and Gly/Arg or Arg/Arg), Lymph nodes, tumor stage, and recurrence status
Fibroblast growth factor receptor 4 genotype
Gly388
Arg388
n
P-value
Positive lymph nodes
N0, N1 and N2
644
295
939
0.010
N3
75
17
92
Tumor stage
T1 and T2
491
86
577
0.0001
T3 and T4
228
226
454
Recurrence status
0
574
208
782
0.0001
1
145
104
249
Table 5 Results from Logistic regression of lymph node, tumor stage and recurrence status on fibroblast growth factor receptor 4 genotype (P < 0.0001)
Fibroblast growth factor receptor 4 genotype
Coeff.
Std. Err.
z
P >|z|
Odds ratio
95% CI
Recurrence status
0.440
0.1693179
2.6
0.009
4.37
0.1080489-0.7717629
positive lymph nodes
1.972
0.1585958
12.44
0.0001
14.43
1.661438-2.283122
Tumor stage
-1,721
0.2903174
-5.93
0.0001
0.24
-2.29047-1.152446
constant
-1.826
0.1234243
-14.79
0.0001
-2.067534-1.58372
Citation: Wimmer E, Ihrler S, Gires O, Streit S, Issing W, Bergmann C. Fibroblast growth factor receptor 4 single nucleotide polymorphism Gly388Arg in head and neck carcinomas. World J Clin Oncol 2019; 10(3): 136-148